FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PKD1-RELB

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PKD1-RELB
FusionPDB ID: 65680
FusionGDB2.0 ID: 65680
HgeneTgene
Gene symbol

PKD1

RELB

Gene ID

5310

5971

Gene namepolycystin 1, transient receptor potential channel interactingRELB proto-oncogene, NF-kB subunit
SynonymsPBP|PC1|Pc-1|TRPP1I-REL|IMD53|IREL|REL-B
Cytomap

16p13.3

19q13.32

Type of geneprotein-codingprotein-coding
Descriptionpolycystin-1autosomal dominant polycystic kidney disease 1 proteinpolycystic kidney disease 1 (autosomal dominant)polycystic kidney disease-associated proteintransient receptor potential cation channel, subfamily P, member 1transcription factor RelBv-rel avian reticuloendotheliosis viral oncogene homolog B (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3)v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gen
Modification date2020031520200315
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000262304, ENST00000423118, 
ENST00000561991, 
ENST00000221452, 
ENST00000505236, ENST00000540120, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 13 X 9=16387 X 6 X 6=252
# samples 147
** MAII scorelog2(14/1638*10)=-3.54843662469604
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/252*10)=-1.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PKD1 [Title/Abstract] AND RELB [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PKD1 [Title/Abstract] AND RELB [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PKD1(2163161)-RELB(45525310), # samples:1
Anticipated loss of major functional domain due to fusion event.PKD1-RELB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-RELB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-RELB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-RELB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePKD1

GO:0045737

positive regulation of cyclin-dependent protein serine/threonine kinase activity

16311606

HgenePKD1

GO:0045944

positive regulation of transcription by RNA polymerase II

16311606

HgenePKD1

GO:0048754

branching morphogenesis of an epithelial tube

12482949

HgenePKD1

GO:0051290

protein heterotetramerization

30093605

HgenePKD1

GO:0061136

regulation of proteasomal protein catabolic process

23001567

HgenePKD1

GO:0198738

cell-cell signaling by wnt

27214281

HgenePKD1

GO:2000045

regulation of G1/S transition of mitotic cell cycle

16311606



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:2163161/chr19:45525310)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PKD1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RELB (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000423118PKD1chr162163161-ENST00000221452RELBchr1945525310+4834319420944291406
ENST00000423118PKD1chr162163161-ENST00000540120RELBchr1945525310+4834319420944291406
ENST00000423118PKD1chr162163161-ENST00000505236RELBchr1945525310+4799319420944291406
ENST00000262304PKD1chr162163161-ENST00000221452RELBchr1945525310+4834319420944291406
ENST00000262304PKD1chr162163161-ENST00000540120RELBchr1945525310+4834319420944291406
ENST00000262304PKD1chr162163161-ENST00000505236RELBchr1945525310+4799319420944291406

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000423118ENST00000221452PKD1chr162163161-RELBchr1945525310+0.0082729860.991727
ENST00000423118ENST00000540120PKD1chr162163161-RELBchr1945525310+0.0082729860.991727
ENST00000423118ENST00000505236PKD1chr162163161-RELBchr1945525310+0.0085579220.991442
ENST00000262304ENST00000221452PKD1chr162163161-RELBchr1945525310+0.0082729860.991727
ENST00000262304ENST00000540120PKD1chr162163161-RELBchr1945525310+0.0082729860.991727
ENST00000262304ENST00000505236PKD1chr162163161-RELBchr1945525310+0.0085579220.991442

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PKD1-RELB

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PKD1chr162163161RELBchr19455253103194993VFNVIYQSAAVFKLSLRDCGGLREVE

Top

Potential FusionNeoAntigen Information of PKD1-RELB in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PKD1-RELB_2163161_45525310.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PKD1-RELBchr162163161chr19455253103194HLA-B35:03SAAVFKLSL0.98650.7744716
PKD1-RELBchr162163161chr19455253103194HLA-B48:01YQSAAVFKL0.98630.5435514
PKD1-RELBchr162163161chr19455253103194HLA-B39:06YQSAAVFKL0.98440.6165514
PKD1-RELBchr162163161chr19455253103194HLA-B08:09SAAVFKLSL0.97750.5365716
PKD1-RELBchr162163161chr19455253103194HLA-B39:01YQSAAVFKL0.97590.8663514
PKD1-RELBchr162163161chr19455253103194HLA-B39:13YQSAAVFKL0.97130.8611514
PKD1-RELBchr162163161chr19455253103194HLA-B38:01YQSAAVFKL0.9630.9339514
PKD1-RELBchr162163161chr19455253103194HLA-B38:02YQSAAVFKL0.96290.9324514
PKD1-RELBchr162163161chr19455253103194HLA-B35:04SAAVFKLSL0.9380.9118716
PKD1-RELBchr162163161chr19455253103194HLA-B35:02SAAVFKLSL0.9380.9118716
PKD1-RELBchr162163161chr19455253103194HLA-B52:01SAAVFKLSL0.92380.7955716
PKD1-RELBchr162163161chr19455253103194HLA-B13:02YQSAAVFKL0.90060.5675514
PKD1-RELBchr162163161chr19455253103194HLA-B13:01YQSAAVFKL0.8830.9029514
PKD1-RELBchr162163161chr19455253103194HLA-B52:01YQSAAVFKL0.15670.9235514
PKD1-RELBchr162163161chr19455253103194HLA-A24:25IYQSAAVFKL0.9980.6107414
PKD1-RELBchr162163161chr19455253103194HLA-A24:20IYQSAAVFKL0.99740.6027414
PKD1-RELBchr162163161chr19455253103194HLA-A24:15IYQSAAVFKL0.99730.6176414
PKD1-RELBchr162163161chr19455253103194HLA-A24:31IYQSAAVFKL0.99670.5587414
PKD1-RELBchr162163161chr19455253103194HLA-A24:14IYQSAAVFKL0.96590.5357414
PKD1-RELBchr162163161chr19455253103194HLA-B48:01YQSAAVFKLSL0.99790.5249516
PKD1-RELBchr162163161chr19455253103194HLA-C15:04SAAVFKLSL0.99970.8829716
PKD1-RELBchr162163161chr19455253103194HLA-C03:08SAAVFKLSL0.99970.9079716
PKD1-RELBchr162163161chr19455253103194HLA-C03:07SAAVFKLSL0.99970.9705716
PKD1-RELBchr162163161chr19455253103194HLA-C15:06SAAVFKLSL0.99960.8879716
PKD1-RELBchr162163161chr19455253103194HLA-C03:19SAAVFKLSL0.99960.9893716
PKD1-RELBchr162163161chr19455253103194HLA-C12:12SAAVFKLSL0.99880.9352716
PKD1-RELBchr162163161chr19455253103194HLA-C04:06SAAVFKLSL0.9980.7377716
PKD1-RELBchr162163161chr19455253103194HLA-C06:03SAAVFKLSL0.99760.9837716
PKD1-RELBchr162163161chr19455253103194HLA-C12:04SAAVFKLSL0.99740.9801716
PKD1-RELBchr162163161chr19455253103194HLA-C08:13SAAVFKLSL0.99610.908716
PKD1-RELBchr162163161chr19455253103194HLA-C08:04SAAVFKLSL0.99610.908716
PKD1-RELBchr162163161chr19455253103194HLA-C04:06YQSAAVFKL0.98720.8317514
PKD1-RELBchr162163161chr19455253103194HLA-C08:03YQSAAVFKL0.98580.9726514
PKD1-RELBchr162163161chr19455253103194HLA-C02:06SAAVFKLSL0.98460.9694716
PKD1-RELBchr162163161chr19455253103194HLA-C03:07YQSAAVFKL0.9820.9738514
PKD1-RELBchr162163161chr19455253103194HLA-C07:13YQSAAVFKL0.97950.9066514
PKD1-RELBchr162163161chr19455253103194HLA-B15:04YQSAAVFKL0.97830.8281514
PKD1-RELBchr162163161chr19455253103194HLA-C07:05YQSAAVFKL0.97830.9457514
PKD1-RELBchr162163161chr19455253103194HLA-B14:03SAAVFKLSL0.97690.6948716
PKD1-RELBchr162163161chr19455253103194HLA-C03:19YQSAAVFKL0.97330.9847514
PKD1-RELBchr162163161chr19455253103194HLA-C08:13YQSAAVFKL0.97320.895514
PKD1-RELBchr162163161chr19455253103194HLA-C08:04YQSAAVFKL0.97320.895514
PKD1-RELBchr162163161chr19455253103194HLA-C03:14SAAVFKLSL0.97220.954716
PKD1-RELBchr162163161chr19455253103194HLA-C07:29YQSAAVFKL0.97070.8592514
PKD1-RELBchr162163161chr19455253103194HLA-C06:03YQSAAVFKL0.97060.9711514
PKD1-RELBchr162163161chr19455253103194HLA-C12:04YQSAAVFKL0.96940.9645514
PKD1-RELBchr162163161chr19455253103194HLA-C04:14YQSAAVFKL0.96890.8532514
PKD1-RELBchr162163161chr19455253103194HLA-B39:12YQSAAVFKL0.96690.8711514
PKD1-RELBchr162163161chr19455253103194HLA-C03:14YQSAAVFKL0.96620.9364514
PKD1-RELBchr162163161chr19455253103194HLA-B39:05YQSAAVFKL0.96570.841514
PKD1-RELBchr162163161chr19455253103194HLA-C08:03SAAVFKLSL0.96450.9617716
PKD1-RELBchr162163161chr19455253103194HLA-C07:10YQSAAVFKL0.95190.9482514
PKD1-RELBchr162163161chr19455253103194HLA-C07:67YQSAAVFKL0.94850.9048514
PKD1-RELBchr162163161chr19455253103194HLA-C07:80YQSAAVFKL0.94850.9048514
PKD1-RELBchr162163161chr19455253103194HLA-C07:19YQSAAVFKL0.94160.5226514
PKD1-RELBchr162163161chr19455253103194HLA-C07:27YQSAAVFKL0.93990.9075514
PKD1-RELBchr162163161chr19455253103194HLA-B35:12SAAVFKLSL0.9380.9118716
PKD1-RELBchr162163161chr19455253103194HLA-C01:30SAAVFKLSL0.91830.963716
PKD1-RELBchr162163161chr19455253103194HLA-C07:46YQSAAVFKL0.90690.8023514
PKD1-RELBchr162163161chr19455253103194HLA-C01:17SAAVFKLSL0.89850.9647716
PKD1-RELBchr162163161chr19455253103194HLA-B39:08YQSAAVFKL0.89430.797514
PKD1-RELBchr162163161chr19455253103194HLA-B39:10SAAVFKLSL0.83460.7354716
PKD1-RELBchr162163161chr19455253103194HLA-C02:06YQSAAVFKL0.83030.8925514
PKD1-RELBchr162163161chr19455253103194HLA-C12:16YQSAAVFKL0.73180.9189514
PKD1-RELBchr162163161chr19455253103194HLA-B15:05YQSAAVFKL0.67290.797514
PKD1-RELBchr162163161chr19455253103194HLA-B14:03YQSAAVFKL0.44420.7049514
PKD1-RELBchr162163161chr19455253103194HLA-A24:02IYQSAAVFKL0.99740.6027414
PKD1-RELBchr162163161chr19455253103194HLA-C03:17AAVFKLSL0.99990.9819816
PKD1-RELBchr162163161chr19455253103194HLA-C03:05AAVFKLSL0.99980.9408816
PKD1-RELBchr162163161chr19455253103194HLA-C16:01AAVFKLSL0.99880.9864816
PKD1-RELBchr162163161chr19455253103194HLA-C15:09SAAVFKLSL0.99970.8829716
PKD1-RELBchr162163161chr19455253103194HLA-C03:04SAAVFKLSL0.99970.9902716
PKD1-RELBchr162163161chr19455253103194HLA-C03:03SAAVFKLSL0.99970.9902716
PKD1-RELBchr162163161chr19455253103194HLA-C03:67SAAVFKLSL0.99960.9771716
PKD1-RELBchr162163161chr19455253103194HLA-C03:17SAAVFKLSL0.99960.9691716
PKD1-RELBchr162163161chr19455253103194HLA-C03:05SAAVFKLSL0.99960.9451716
PKD1-RELBchr162163161chr19455253103194HLA-C15:05SAAVFKLSL0.99950.8566716
PKD1-RELBchr162163161chr19455253103194HLA-C15:02SAAVFKLSL0.99940.8459716
PKD1-RELBchr162163161chr19455253103194HLA-C03:02SAAVFKLSL0.99910.9682716
PKD1-RELBchr162163161chr19455253103194HLA-C16:04SAAVFKLSL0.99880.9725716
PKD1-RELBchr162163161chr19455253103194HLA-C12:03SAAVFKLSL0.99880.9624716
PKD1-RELBchr162163161chr19455253103194HLA-C12:02SAAVFKLSL0.99750.9539716
PKD1-RELBchr162163161chr19455253103194HLA-C07:04SAAVFKLSL0.99560.9338716
PKD1-RELBchr162163161chr19455253103194HLA-B27:06YQSAAVFKL0.99450.7552514
PKD1-RELBchr162163161chr19455253103194HLA-C03:06SAAVFKLSL0.99430.9909716
PKD1-RELBchr162163161chr19455253103194HLA-C16:01SAAVFKLSL0.99310.9773716
PKD1-RELBchr162163161chr19455253103194HLA-B15:24YQSAAVFKL0.99240.8357514
PKD1-RELBchr162163161chr19455253103194HLA-C04:04YQSAAVFKL0.98650.8362514
PKD1-RELBchr162163161chr19455253103194HLA-B35:13SAAVFKLSL0.9860.7832716
PKD1-RELBchr162163161chr19455253103194HLA-C08:01YQSAAVFKL0.98580.9726514
PKD1-RELBchr162163161chr19455253103194HLA-C02:10SAAVFKLSL0.98520.9798716
PKD1-RELBchr162163161chr19455253103194HLA-C02:02SAAVFKLSL0.98520.9798716
PKD1-RELBchr162163161chr19455253103194HLA-B07:13SAAVFKLSL0.98360.8566716
PKD1-RELBchr162163161chr19455253103194HLA-C16:02SAAVFKLSL0.98320.9897716
PKD1-RELBchr162163161chr19455253103194HLA-B27:09YQSAAVFKL0.98140.8052514
PKD1-RELBchr162163161chr19455253103194HLA-C15:05YQSAAVFKL0.98120.8275514
PKD1-RELBchr162163161chr19455253103194HLA-B39:02YQSAAVFKL0.98050.8676514
PKD1-RELBchr162163161chr19455253103194HLA-B08:12SAAVFKLSL0.98050.6322716
PKD1-RELBchr162163161chr19455253103194HLA-B39:31YQSAAVFKL0.97490.8699514
PKD1-RELBchr162163161chr19455253103194HLA-C17:01YQSAAVFKL0.96880.8779514
PKD1-RELBchr162163161chr19455253103194HLA-C08:01SAAVFKLSL0.96450.9617716
PKD1-RELBchr162163161chr19455253103194HLA-B38:05YQSAAVFKL0.9630.9339514
PKD1-RELBchr162163161chr19455253103194HLA-C07:02YQSAAVFKL0.94850.9048514
PKD1-RELBchr162163161chr19455253103194HLA-C07:04YQSAAVFKL0.94730.8795514
PKD1-RELBchr162163161chr19455253103194HLA-C07:17YQSAAVFKL0.94580.9283514
PKD1-RELBchr162163161chr19455253103194HLA-C03:67YQSAAVFKL0.94310.9686514
PKD1-RELBchr162163161chr19455253103194HLA-B35:09SAAVFKLSL0.9380.9118716
PKD1-RELBchr162163161chr19455253103194HLA-C06:06YQSAAVFKL0.92410.9795514
PKD1-RELBchr162163161chr19455253103194HLA-B15:73YQSAAVFKL0.92350.7729514
PKD1-RELBchr162163161chr19455253103194HLA-C01:03SAAVFKLSL0.91730.947716
PKD1-RELBchr162163161chr19455253103194HLA-C01:02SAAVFKLSL0.91150.9637716
PKD1-RELBchr162163161chr19455253103194HLA-C06:17YQSAAVFKL0.90090.9628514
PKD1-RELBchr162163161chr19455253103194HLA-C06:02YQSAAVFKL0.90090.9628514
PKD1-RELBchr162163161chr19455253103194HLA-C07:22YQSAAVFKL0.88050.5392514
PKD1-RELBchr162163161chr19455253103194HLA-B39:11YQSAAVFKL0.85820.7677514
PKD1-RELBchr162163161chr19455253103194HLA-B15:30YQSAAVFKL0.83810.7086514
PKD1-RELBchr162163161chr19455253103194HLA-C06:08YQSAAVFKL0.81960.9663514
PKD1-RELBchr162163161chr19455253103194HLA-C17:01SAAVFKLSL0.81940.9419716
PKD1-RELBchr162163161chr19455253103194HLA-C02:10YQSAAVFKL0.78330.9476514
PKD1-RELBchr162163161chr19455253103194HLA-C02:02YQSAAVFKL0.78330.9476514
PKD1-RELBchr162163161chr19455253103194HLA-B35:13YQSAAVFKL0.7670.8051514
PKD1-RELBchr162163161chr19455253103194HLA-C12:02YQSAAVFKL0.76670.926514
PKD1-RELBchr162163161chr19455253103194HLA-B48:02YQSAAVFKL0.7570.8926514
PKD1-RELBchr162163161chr19455253103194HLA-B15:20YQSAAVFKL0.67940.8998514
PKD1-RELBchr162163161chr19455253103194HLA-B35:28YQSAAVFKL0.66470.9081514
PKD1-RELBchr162163161chr19455253103194HLA-B15:09YQSAAVFKL0.55350.7281514
PKD1-RELBchr162163161chr19455253103194HLA-B07:13YQSAAVFKL0.09250.8071514

Top

Potential FusionNeoAntigen Information of PKD1-RELB in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PKD1-RELB_2163161_45525310.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PKD1-RELBchr162163161chr19455253103194DRB1-0901NVIYQSAAVFKLSLR217
PKD1-RELBchr162163161chr19455253103194DRB1-0904NVIYQSAAVFKLSLR217
PKD1-RELBchr162163161chr19455253103194DRB1-0904VFNVIYQSAAVFKLS015
PKD1-RELBchr162163161chr19455253103194DRB1-0905NVIYQSAAVFKLSLR217
PKD1-RELBchr162163161chr19455253103194DRB1-0905VFNVIYQSAAVFKLS015
PKD1-RELBchr162163161chr19455253103194DRB1-0907NVIYQSAAVFKLSLR217
PKD1-RELBchr162163161chr19455253103194DRB1-0907VFNVIYQSAAVFKLS015
PKD1-RELBchr162163161chr19455253103194DRB1-0909NVIYQSAAVFKLSLR217

Top

Fusion breakpoint peptide structures of PKD1-RELB

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7570QSAAVFKLSLRDCGPKD1RELBchr162163161chr19455253103194

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PKD1-RELB

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7570QSAAVFKLSLRDCG-7.15543-7.26883
HLA-B14:023BVN7570QSAAVFKLSLRDCG-4.77435-5.80965
HLA-B52:013W397570QSAAVFKLSLRDCG-6.80875-6.92215
HLA-B52:013W397570QSAAVFKLSLRDCG-4.20386-5.23916
HLA-A11:014UQ27570QSAAVFKLSLRDCG-7.5194-8.5547
HLA-A11:014UQ27570QSAAVFKLSLRDCG-6.9601-7.0735
HLA-A24:025HGA7570QSAAVFKLSLRDCG-7.52403-7.63743
HLA-A24:025HGA7570QSAAVFKLSLRDCG-5.82433-6.85963
HLA-B27:056PYJ7570QSAAVFKLSLRDCG-3.28285-4.31815
HLA-B44:053DX87570QSAAVFKLSLRDCG-5.91172-6.94702
HLA-B44:053DX87570QSAAVFKLSLRDCG-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PKD1-RELB

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PKD1-RELBchr162163161chr1945525310414IYQSAAVFKLCAGAGCGCGGCGGTCTTCAAGCTCTCACTC
PKD1-RELBchr162163161chr1945525310514YQSAAVFKLAGCGCGGCGGTCTTCAAGCTCTCACTC
PKD1-RELBchr162163161chr1945525310516YQSAAVFKLSLAGCGCGGCGGTCTTCAAGCTCTCACTCCGGGAT
PKD1-RELBchr162163161chr1945525310716SAAVFKLSLGCGGTCTTCAAGCTCTCACTCCGGGAT
PKD1-RELBchr162163161chr1945525310816AAVFKLSLGTCTTCAAGCTCTCACTCCGGGAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PKD1-RELBchr162163161chr1945525310015VFNVIYQSAAVFKLSAATGTCATTTATCAGAGCGCGGCGGTCTTCAAGCTCTCACTCCGG
PKD1-RELBchr162163161chr1945525310217NVIYQSAAVFKLSLRATTTATCAGAGCGCGGCGGTCTTCAAGCTCTCACTCCGGGATTGT

Top

Information of the samples that have these potential fusion neoantigens of PKD1-RELB

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LGGPKD1-RELBchr162163161ENST00000262304chr1945525310ENST00000221452TCGA-HT-8110

Top

Potential target of CAR-T therapy development for PKD1-RELB

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PKD1-RELB

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PKD1-RELB

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource